The first-generation reversible EGFR-TKIs, gefitinib and erlotinib, have shown benefits in non-small cell lung cancer (NSCLC) patients carrying EGFR-sensitizing mutations (L858R in exon 21 and exon 19 deletions) [43]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.